Serum Angiopoietin-2 level increase differs between polytraumatized patients with and without central nervous system injuries.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
07 11 2023
07 11 2023
Historique:
received:
04
02
2023
accepted:
23
10
2023
medline:
9
11
2023
pubmed:
8
11
2023
entrez:
7
11
2023
Statut:
epublish
Résumé
Since endothelial cells rapidly release Angiopoietin-2 (Ang-2) in response to vascular injury and inflammatory stimuli, we aimed to investigate if its serum levels increase in polytraumatized patients. Our cohort study evaluated 28 blunt polytrauma survivors (mean age, 38.4 years; median ISS, 34) who were directly admitted to our level I trauma center in 2018. We assessed the serum Ang-2 level at admission and on days 1, 3, 5, 7, and 10 during hospitalization. Ang-2 was released into the circulation immediately after polytrauma. At admission (day 0), it amounted to 8286 ± 5068 pg/mL, three-and-a-half times the reference value of 2337 ± 650 pg/mL assessed in a healthy control group. Subgroup analysis provided a higher mean Ang-2 level in the CNSI group combining all patients suffering a brain or spinal cord injury compared to the non-CNSI group solely on day 0 [11083 ± 5408 pg/mL versus 3963 ± 2062 pg/mL; p < 0.001]. Whereas the mean Ang-2 level increased only in the non-CNSI group from day 0 to day 3 (p = 0.009), the respective curves showed similar continuous decreases starting with day 3. Multivariate logistic regression analysis revealed an association between the Ang-2 day 0 level and the presence of a CNSI (OR = 1.885; p = 0.048). ROC analysis provided a cutoff level of 5352 pg/mL. In our study group, serum Ang-2 levels assessed at admission differed between polytraumatized patients with and without brain or spinal cord injuries. Based on our findings, we consider serum Ang-2 levels an effective biomarker candidate for indicating CNSI in these patients at admission, worthy of further evaluation in large multicenter studies.
Identifiants
pubmed: 37935720
doi: 10.1038/s41598-023-45688-x
pii: 10.1038/s41598-023-45688-x
pmc: PMC10630405
doi:
Substances chimiques
Angiopoietin-1
0
Angiopoietin-2
0
Biomarkers
0
VPS51 protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
19338Informations de copyright
© 2023. The Author(s).
Références
J Crohns Colitis. 2018 Feb 28;12(3):289-297
pubmed: 29121178
Cancer. 1950 Jan;3(1):32-5
pubmed: 15405679
Am J Respir Crit Care Med. 2013 Apr 1;187(7):736-42
pubmed: 23328529
Trauma Surg Acute Care Open. 2017 Aug 28;2(1):e000121
pubmed: 29766112
Neuroscience. 2012 Jan 27;202:454-64
pubmed: 22020092
J Cell Physiol. 2009 Mar;218(3):612-22
pubmed: 19016245
Arterioscler Thromb Vasc Biol. 2006 May;26(5):1002-7
pubmed: 16469951
Biomed Res Int. 2018 Jul 19;2018:9387809
pubmed: 30105266
Mediators Inflamm. 2018 Jun 12;2018:1739615
pubmed: 30008611
Semin Cell Dev Biol. 2015 Feb;38:2-6
pubmed: 25681530
J Spinal Cord Med. 2015 Nov;38(6):729-44
pubmed: 24968203
Nat Rev Mol Cell Biol. 2009 Mar;10(3):165-77
pubmed: 19234476
Blood. 2004 Jun 1;103(11):4150-6
pubmed: 14976056
MMWR Surveill Summ. 2017 Mar 17;66(9):1-16
pubmed: 28301451
J Neurotrauma. 2021 May 1;38(9):1203-1224
pubmed: 33292072
Cell Mol Neurobiol. 2005 Feb;25(1):5-23
pubmed: 15962506
Ann Surg. 2008 Feb;247(2):320-6
pubmed: 18216540
Am J Respir Crit Care Med. 2018 Jul 15;198(2):220-231
pubmed: 29447449
Neurosurg Focus. 2022 Feb;52(2):E10
pubmed: 35104790
Trends Immunol. 2006 Dec;27(12):552-8
pubmed: 17045842
Exp Lung Res. 2016 Sep;42(7):335-345
pubmed: 27585839
Clin Appl Thromb Hemost. 2018 Dec;24(9_suppl):269S-276S
pubmed: 30370780
Dev Neurosci. 2019;41(3-4):177-192
pubmed: 31553988
Ther Adv Respir Dis. 2020 Jan-Dec;14:1753466620905274
pubmed: 32043429
Nat Rev Dis Primers. 2017 Apr 27;3:17018
pubmed: 28447605
Pathophysiology. 2013 Feb;20(1):15-21
pubmed: 22633746
Lab Invest. 2005 Oct;85(10):1189-98
pubmed: 16056241
Int Neurourol J. 2016 Dec;20(4):288-295
pubmed: 28043115
World J Emerg Med. 2011;2(4):287-90
pubmed: 25215025
Neurotherapeutics. 2019 Oct;16(4):1167-1182
pubmed: 31077039
Cytokine. 2008 Nov;44(2):310-3
pubmed: 18952457
Cell Commun Signal. 2020 Mar 17;18(1):46
pubmed: 32183816
J Head Trauma Rehabil. 2020 Sep/Oct;35(5):317-323
pubmed: 32881765
Shock. 2008 Jun;29(6):656-61
pubmed: 18091573
J Neuroimmune Pharmacol. 2006 Sep;1(3):223-36
pubmed: 18040800
Blood. 2011 May 12;117(19):5033-43
pubmed: 21266719
Exp Ther Med. 2013 Mar;5(3):937-941
pubmed: 23408510
J Trauma. 2010 May;68(5):1121-7
pubmed: 20038857
Front Med (Lausanne). 2016 Nov 28;3:64
pubmed: 27965960
Ann N Y Acad Sci. 2015 Jul;1347:45-51
pubmed: 25773744
Cells. 2019 May 17;8(5):
pubmed: 31108880
Front Immunol. 2019 Nov 20;10:2723
pubmed: 31824504
J Cell Mol Med. 2020 Jan;24(1):139-148
pubmed: 31568637